Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

Summer Street:

"ARIA appears to have the support of its clinicians regarding the drug's safety. The larger challenge will be the label changes and REMS program as they work with the FDA. We believe the drug provides a clear unmet need and will return in time."

Summer Street maintained an Neutral rating on ARIAD Pharmaceuticals (NASDAQ: ARIA). A consultant with the firm said there was no new information from the PACE data at ASH. For analyst Carol Werther, that can be taken positively or negatively.

http://www.streetinsider.com/Analyst+Comments/ARIAD+Pharma+(ARIA)%3A+No+New+Information+From+PACE+Data+at+ASH+-+Summer+Street/8963679.html